Latest News From Lumira Ventures

Endotronix Announces Partnership with Tyndall National Institute to Advance Chronic Disease Management

Jennifer Schram Endotronix, Portfolio News, Press Release, Uncategorized

PRNewswire — Endotronix Ireland Limited, a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), announced today an Enterprise Ireland Industry Partnership project is a collaboration with Tyndall National Institute, a leading European Deep Tech research center in integrated …

Zymeworks Announces Updated Single Agent Data for HER2-Targeted Bispecific Antibody ZW25 at ESMO Congress 2019

Jennifer Schram Portfolio News, Press Release, Zymeworks

BARCELONA, Spain–(BUSINESS WIRE) — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated data from the ongoing multi-center Phase 1 clinical trial evaluating ZW25 in patients with HER2‑expressing solid tumors, including biliary tract cancer (BTC), …

Trial Results Show Trilaciclib Decreases Myelosuppression in Extensive-Stage Small Cell Lung Cancer (SCLC) Patients

Jennifer Schram G1 Therapeutics, Portfolio News, Press Release

This global, randomized, double-blind, placebo-controlled, multicenter, Phase 2 study (NCT03041311) assessed the potential of trilaciclib to reduce the incidence and consequences of chemotherapy-induced myelosuppression in patients with newly diagnosed extensive-stage small-cell lung cancer (ES-SCLC) treated with etoposide, carboplatin and atezolizumab …

G1 Therapeutics presents data from Phase 2 mTNBC trial for trilaciclib at ESMO19

Jennifer Schram G1 Therapeutics, Portfolio News, Press Release

RESEARCH TRIANGLE PARK, N.C. and BARCELONA, Spain, Sept. 28, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported preliminary overall survival (OS) data from the company’s randomized Phase 2 trial of trilaciclib in combination with chemotherapy for the treatment of metastatic …

Satsuma Pharmaceuticals Completes $90.8M Initial Public Offering

Jennifer Schram Main Page, Portfolio News, Press Release, Satsuma Pharmaceuticals

SOUTH SAN FRANCISCO, Calif. — Satsuma Pharmaceuticals, Inc. (“Satsuma” or the “Company”) (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced the closing of the Company’s previously announced initial public offering …

Health Quality Ontario Recommends Public Funding of Gliolan®

Jennifer Schram Medexus Pharmaceuticals, Portfolio News, Press Release

MONTREAL, Sept. 12, 2019 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) announces that Health Quality Ontario, under the guidance of the Ontario Health Technology Advisory Committee, has recommended public funding of Gliolan® (5-aminolevulinic acid hydrochloride) …